Thiotepa
- Generic Name
- Thiotepa
- Brand Names
- Tepadina, Thiotepa Riemser
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N3PS
- CAS Number
- 52-24-4
- Unique Ingredient Identifier
- 905Z5W3GKH
- Background
N,N'N'-triethylenethiophosphoramide (ThioTEPA) is a cancer chemotherapeutic member of the alkylating agent group, now in use for over 50 years. It is a stable derivative of N,N',N''- triethylenephosphoramide (TEPA). It is mostly used to treat breast cancer, ovarian cancer and bladder cancer. It is also used as conditioning for Bone marrow transplantation. It...
- Indication
ThioTEPA is used a as conditioning treatment prior to allogeneic or autologous haematopoietic progenitor cell transplantation (HPCT) in haematological diseases in adult and paediatric patients. Also, when high dose chemotherapy with HPCT support it is appropriate for the treatment of solid tumours in adult and paediatric patients.
- Associated Conditions
- Adenocarcinoma of the Ovaries, Breast Adenocarcinoma, Papillary transitional cell carcinoma of bladder, Malignant effusion
- Associated Therapies
- -
Phase 2 Haplotype Mismatched HSCT in Patients With Hematological Malignancies
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2018-04-10
- Lead Sponsor
- Sherif S. Farag
- Target Recruit Count
- 9
- Registration Number
- NCT00593554
- Locations
- 🇺🇸
Indiana University Cancer Center, Indianapolis, Indiana, United States
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
- Conditions
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideRadiation: External Beam Radiation TherapyBiological: FilgrastimDrug: IsotretinoinOther: Laboratory Biomarker AnalysisDrug: MelphalanProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyDrug: Topotecan HydrochlorideDrug: ThiotepaDrug: Vincristine Sulfate Liposome
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 665
- Registration Number
- NCT00567567
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma
- Conditions
- Interventions
- Procedure: Autologous Bone Marrow TransplantationProcedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: EtoposideBiological: FilgrastimProcedure: In Vitro-Treated Peripheral Blood Stem Cell TransplantationRadiation: Radiation TherapyDrug: ThiotepaDrug: Vincristine Sulfate
- First Posted Date
- 2007-11-07
- Last Posted Date
- 2024-10-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 60
- Registration Number
- NCT00554788
- Locations
- 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸Children's Hospital of Alabama, Birmingham, Alabama, United States
🇺🇸University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors
- Conditions
- Adult Acute Lymphoblastic Leukemia in RemissionAdult Acute Myeloid Leukemia in RemissionAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Nasal Type Extranodal NK/T-cell LymphomaChildhood Acute Lymphoblastic Leukemia in Remission
- Interventions
- First Posted Date
- 2007-09-28
- Last Posted Date
- 2021-04-22
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 174
- Registration Number
- NCT00536601
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Combination Chemotherapy in Treating Young Patients With Relapsed or Refractory Acute Leukemia
- Conditions
- Interventions
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2013-11-14
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 23
- Registration Number
- NCT00462787
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases
- Conditions
- First Posted Date
- 2007-03-22
- Last Posted Date
- 2017-05-24
- Lead Sponsor
- Fred Hutchinson Cancer Center
- Target Recruit Count
- 1
- Registration Number
- NCT00450983
- Locations
- 🇺🇸
Seattle Cancer Care Alliance, Seattle, Washington, United States
🇺🇸Fred Hutchinson Cancer Research Center, Seattle, Washington, United States
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
- First Posted Date
- 2007-02-07
- Last Posted Date
- 2022-05-17
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 23
- Registration Number
- NCT00432094
- Locations
- 🇺🇸
Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Purged Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2007-01-31
- Last Posted Date
- 2013-04-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00429182
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
- Conditions
- Interventions
- First Posted Date
- 2007-01-18
- Last Posted Date
- 2022-12-27
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT00423514
- Locations
- 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
Combination Chemotherapy With or Without Etoposide Followed By an Autologous Stem Cell Transplant in Treating Young Patients With Previously Untreated Malignant Brain Tumors
- Conditions
- Interventions
- Drug: carboplatinDrug: temozolomideDrug: cisplatinDrug: thiotepaDrug: cyclophosphamideDrug: vincristine sulfateDrug: etoposideProcedure: autologous bone marrow transplantationDrug: methotrexateProcedure: autologous hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationRadiation: radiation therapy
- First Posted Date
- 2006-10-26
- Last Posted Date
- 2013-12-18
- Lead Sponsor
- Children's Hospital Los Angeles
- Target Recruit Count
- 120
- Registration Number
- NCT00392886
- Locations
- 🇺🇸
Childrens Hospital Los Angeles, Los Angeles, California, United States
🇦🇺Princess Margaret Hospital for Children, Perth, Western Australia, Australia
🇺🇸Children's Hospital of Orange County, Orange, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.